Some more positive news from Incannex this morning that has bumped the share price up over 13% at the time of writing. IHL-42x has shown positive results in low dose administration for the treatment of sleep apnea. Sleep apnea is a huge market that is currently treated by machines so a medication could be a huge game changer in how it is treated in the future. The fact that low dosages are having such a positive impact suggest this could also limit any impact in positive test results for cannabis in roadside drug tests.

Highlights:

• IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three

doses that were assessed

• Low dose IHL-42X exhibited superior safety and efficacy metrics to mid and high doses

• Low dose IHL-42X reduced AHI by an average of 50.7% compared to baseline with 25% of

participants experiencing a reduction in the apnoea hypopnea index of greater that 80%

• Oxygen desaturation index was reduced by 59.7% relative to baseline while taking low dose

IHL-42X, improving sleep quality and reducing cardiovascular stress

• In low dose IHL-42X samples, THC concentrations in blood were well below the limits for

impaired driving the morning after dose administration

• IHL-42X was well tolerated – low dose IHL-42X was observed to have a lower number of total

treatment emergent adverse events than placebo

• Low dose IHL-42X reduced AHI substantially more effectively than is reported for the

component active pharmaceutical ingredients, dronabinol and acetazolamide, as unregistered

monotherapies.

It will be interesting to see what this does for the share price on the NASDAQ overnight